Floatz logo

ly03010

Psychotic Disorders

Luye Pharma Group Ltd.Phase 1Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
81/ 100

Competitive context

36 Active assets in the Psychotic Disorders cohort.

Asset / SponsorPhaseRating
Olanzapine
Shanghai Jiao Tong University School of Medicine
Phase 4BBB
Risperdal
Northwell Health
Phase 4BBB
Paliperidone Palmitate 3-Month Formulation
Consorcio Centro de Investigación Biomédica en Red (CIBER)
Phase 4BBB
Haloperidol
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Phase 4BBB
Asenapine
Centre de Recherche de l'Institut Universitaire en Santé Mentale de Québec
Phase 4BBB

View all 50 →

Same molecule, other indications

ly03010 is also rated in:

mood disorderDormant
CCC
Indicative ·
52 / 100
View asset →
Antipsychotic AgentsDormant
CCC
Indicative ·
52 / 100
View asset →
Physiological Effects of DrugsDormant
CCC
Indicative ·
52 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →